



GILEAD

Advancing Therapeutics.
Improving Lives.

Amendment to Memorandum of Understanding

This Amendment to Memorandum of Understanding (this "**Amendment**") is effective as of November 16, 2015 (the "**Amendment Effective Date**") by and between Gilead Sciences Ireland UC ("**Gilead**") and the Ministry of Labour, Health and Social Affairs of the Republic of Georgia (the "**MOH**").

1. Background. Gilead the MOH entered into that certain Memorandum of Understanding effective April 21, 2015 (the "**MOU**") pursuant to which Gilead agreed to supply certain quantities of Sovaldi pursuant to an Initial Program (as defined in the MOU).

2. Definitions.


- a. "**Product**" means (notwithstanding Section 2 of the MOU) individually and collectively:
(i) Sovaldi (tablets of 400 mg of sofosbuvir); and (b) Harvoni (tablets of 400 mg of sofosbuvir and 90 mg of ledipasvir).
- b. "**Qualified Patient**" means (notwithstanding Section 3 of the MOU) any individual that:
(i) is infected with HCV; (ii) resides within the Republic of Georgia; and (ii) receives Product at no cost through the MOH.
- c. All other capitalized terms not otherwise defined herein will have the meanings assigned to them in the MOU.

3. Supply of Product. Notwithstanding anything to the contrary set forth in the MOU, Gilead agrees to supply to the MOH additional bottles of Sovaldi and/or Harvoni to treat up to 1,700 Qualified Patients per month as part of the Initial Program pursuant the terms of the MOU until the earlier of (a) March 31, 2016 or (b) the date on which the Parties execute with the CDC all relevant documentation to implement the final HCV Program.

4. General. This Amendment, together with the MOU, constitutes the entire and only agreement between the Parties relating to the subject matter hereof, and supersedes all prior negotiations, representations, agreements and understandings with respect to such subject matter.

IN WITNESS WHEREOF, authorized representatives of the Parties have executed this Amendment as of the Amendment Effective Date.

**ON BEHALF OF
GILEAD SCIENCES IRELAND UC**

By: 

Name: Gregg Alton

Title: Executive Vice President, Corporate and
Medical Affairs, Gilead Sciences, Inc.

**ON BEHALF OF THE MINISTRY OF
LABOUR, HEALTH AND SOCIAL AFFAIRS
OF GEORGIA**

By: 

Name: Valeri Kvaratskhelia

Title: Republic of Georgia Deputy Health
Minister